Deepika Polineni M.D., M.P.H.

Profile picture
Associate Professor of Pediatrics, Allergy and Pulmonary Medicine
School of MedicineAllergy and Pulmonary Medicine

phone: (314) 454-2694


  • BA, University of Missouri-Kansas City2001
  • MD, University of Missouri-Kansas City | School of Medicine2004
  • MPH, Boston University | School of Public Health2003


  • Internship (Internal Medicine), University of Michigan Health System2004 - 2005
  • Residency (Internal Medicine), University of Michigan Health System2005 - 2007
  • Post Doctoral Fellowship, Washington University School of Medicine2007 - 2008
  • Clinical Fellowship (Pulmonary Medicine), University of North Carolina Hospitals2008 - 2010
  • The Jayhawk Way Program, Certificate Course, sponsored by University of Kansas Medical Center, primary area of focus: Administration/ Leadership2019 - 2019
  • Leadership & Management in Health, Certificate Course, sponsored by University of Washington, Seattle, primary area of focus: Administration/ Leadership2020 - 2020
  • Leadership by Design Program, Certificate Course, sponsored by University of Kansas Medical Center, primary area of focus: Administration/ Leadership2020 - 2020
  • Classroom & Clinical Teaching Development Program, Workshop, sponsored by University of Kansas Medical Center, primary area of focus: Teaching Skills2020 - 2021
  • The Life Coach School Certification Program, Certificate Course, sponsored by The Life Coach School, primary area of focus: Administration/Leadership, Advancing Teaching2020 - 2021

Licensure and Board Certification

  • 2004 - 2007Michigan Medical License
  • 2007 - 2017Internal Medicine, American Board of Internal Medicine
  • 2010 - 2014North Carolina Medical License
  • 2011 - 2022Pulmonary Medicine Certification, American Board of Internal Medicine
  • 2014 - PresKansas Medical License
  • 2022 - PresMissouri Medical License

Honors and Awards

  • "Bright Flight" Scholarship Missouri Department of Higher Education The Missouri Higher Education Academic Scholarship Program1996
  • Golden Key National Honor Society University of Missouri-Kansas City1997
  • Travel Abroad Scholarship University of Missouri-Kansas City, Comparative health policy study in Sweden and Denmark: “Health Care and Social Services in Sweden and Denmark"2000
  • Clerkship Honors University of Missouri-Kansas City School of Medicine, Internal Medicine, General Surgery, Family Medicine, Clinical Nephrology, Behavioral Science, Medical Biostatistics, History of Medicine, “Hospital Team: Psychiatry”2000 - 2003
  • Staff Recognition Award “You’re Super” Award, University of Michigan Hospitals System, Ann Arbor Michigan, Chosen by University of Michigan Hospital System staff for exceptional care of patients and families2006
  • Travel Award & Scholarship Cystic Fibrosis Foundation, North American Cystic Fibrosis Conference (Adult fellows’ category)2008
  • “Highlighted Abstract” for National Presentation American Thoracic Society Section on Clinical Problems2010
  • Philip A. Bromberg Chief’s Award for Research Excellence University of North Carolina at Chapel Hill2010
  • UNC Healthcare High 5 Award University of North Carolina Hospitals, For Outstanding Staff Service and Performance2010
  • Second Place Award for Outstanding Clinical Research Astra Zeneca 8th Annual Young Investigators’ , Respiratory Research Forum2011
  • Faculty Research Scholar University of Kansas Department of Internal Medicine - Office of Scholarly Academic & Research Mentoring2014 - 2016
  • Clinical Translation Science Award Frontiers: Heartland Institute for Clinical and Translational Research, University of Kansas Medical Center2015 - 2016
  • Frontiers Scholar Frontiers: Heartland Institute for Clinical and Translational Research2015 - 2016
  • Member Alpha Omega Alpha2017 - Pres
  • Quality Care Award: Recognizing Outstanding Quality Improvement Processes and Accomplishments Cystic Fibrosis Foundation2017
  • Clinical Research Scholar Program Awardee Cystic Fibrosis Foundation2018 - 2021
  • Gold Humanism Honor Society Nominee (Nominated) Gold Humanism Honor Society2020
  • President Elect AAMC's Group on Women in Medicine & Science, University of Kansas Chapter2021
  • Topic Editor Women in Science: Genetics, Frontiers in Genetics2021
  • WIMS Soaring Star Women in Medicine and Science award that acknowledges women faculty in the University of Kansas School of Medicine who have achieved significant career accomplishments2021
  • President, AAMC's Group on Women in Medicine & Science, University of Kansas Chapter2021 - 2022
  • University of Kansas Scholarly Achievement Award Nominee2022

Recent Publications view all (27)

Publication Co-Authors

  1. Feasibility and acceptability of a CF-specific cognitive-behavioral preventive intervention for adults integrated into team-based care. Pediatr Pulmonol. 2022;57(11):2781-2790. PMID:35931665 
  2. Sex and Gender in lung diseases and sleep disorders: A state of the art review. Part 2. Chest. 2022. PMID:36183784 
  3. Trabecular bone score in people with cystic fibrosis. Osteoporos Int. 2022;33(5):1137-1145. PMID:35013769 
  4. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial. Am J Respir Crit Care Med. 2022;205(5):529-539. PMCID:PMC8906485  PMID:34784492 
  5. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. Reply. N Engl J Med. 2021;385(23):2208. PMID:34874646 
  6. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. N Engl J Med. 2021;385(9):815-825. PMCID:PMC8982185  PMID:34437784 
  7. Cystic fibrosis. Lancet. 2021;397(10290):2195-2211. PMID:34090606 
  8. A pilot study of cystic fibrosis exacerbation response phenotypes reveals contrasting serum and sputum iron trends. Sci Rep. 2021;11(1):4897. PMCID:PMC7921142  PMID:33649353 
  9. Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial. Am J Respir Crit Care Med. 2021;203(3):381-385. PMCID:PMC8020728  PMID:32969708 
  10. Mining GWAS and eQTL data for CF lung disease modifiers by gene expression imputation. PLoS One. 2020;15(11):e0239189. PMCID:PMC7703903  PMID:33253230 
  11. Gender Equity. J Cyst Fibros. 2020;19(2):328-329. PMID:32527497 
  12. Losartan Rescues Inflammation-related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis. Am J Respir Crit Care Med. 2020;201(3):313-324. PMCID:PMC6999107  PMID:31613648 
  13. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N Engl J Med. 2019;381(19):1809-1819. PMCID:PMC7282384  PMID:31697873 
  14. Perspectives on anemia and iron deficiency from the cystic fibrosis care community. Pediatr Pulmonol. 2019;54(7):939-940. PMCID:PMC6591048  PMID:30924325 
  15. Unraveling the CFTR Function-Phenotype Connection for Precision Treatment in Cystic Fibrosis. Am J Respir Crit Care Med. 2019;199(9):1053-1054. PMCID:PMC6515879  PMID:30939246 
  16. Aztreonam Lysine Inhalation Solution in Cystic Fibrosis. Clin Med Insights Circ Respir Pulm Med. 2019;13:1179548419842822. PMCID:PMC6463232  PMID:31019373 
  17. Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci. PLoS Genet. 2019;15(2):e1008007. PMCID:PMC6407791  PMID:30807572 
  18. Analysis of a large cohort of cystic fibrosis patients with severe liver disease indicates lung function decline does not significantly differ from that of the general cystic fibrosis population. PLoS One. 2018;13(10):e0205257. PMCID:PMC6181334  PMID:30307979 
  19. Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;197(12):e24-e39. PMCID:PMC6006411  PMID:29905515 
  20. In statistics we trust: Towards the careful derivation and interpretation of meaningful survival estimates in cystic fibrosis. J Cyst Fibros. 2018;17(2):133-134. PMCID:PMC6445384  PMID:29396024 
  21. Chasing Zero: Increasing Infection Control Compliance on an Inpatient Cystic Fibrosis Unit. J Nurs Care Qual. 2018;33(1):67-71. PMID:28658183 
  22. Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity. Am J Respir Crit Care Med. 2018;197(1):79-93. PMCID:PMC5765386  PMID:28853905 
  23. Accuracy of Nasal Nitric Oxide Measurement as a Diagnostic Test for Primary Ciliary Dyskinesia. A Systematic Review and Meta-analysis. Ann Am Thorac Soc. 2017;14(7):1184-1196. PMCID:PMC6137897  PMID:28481653 
  24. Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation. J Clin Apher. 2016;31(4):347-52. PMID:26031713 
  25. Treatment recommendations in Primary Ciliary Dyskinesia. Paediatr Respir Rev. 2016;18:39-45. PMID:26586601 
  26. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med. 2008;14(6):633-40. PMCID:PMC2575848  PMID:18488036 
  27. An interactive web-based curriculum on evidence-based medicine: design and effectiveness. Fam Med. 2006;38(2):126-32. PMID:16450235 
Last updated: 12/02/2022
© 2022 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130